Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Investigating the Novel Combination of the Innate Cell Engager (ICE®) Acimtamig with Off-the-Shelf Allogeneic Natural Killer Cells AlloNK® in Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Initial Results of the Phase 2 Luminice-203 Study

Joseph Maakaron, Dipenkumar Modi, Matthew Mei, Tatyana Feldman, Gunjan L. Shah, Amitkumar N. Mehta, Craig S. Sauter, Rashmi Khanal, Stefan K. Barta, Michael Emig, Lydia Wunderle, Andre Overesch, Alexandra Vasile, Jennifer Rubel, Thorsten Graef, Heather Raymon, Alison Moskowitz

Blood (2024) 144 (Supplement 1): 3052.

https://doi.org/10.1182/blood-2024-193896

Published: 2024

Journal Articles

A Novel Dual-Antigen Targeting Approach Enables Off-the-Shelf CAR NK Cells to Effectively Recognize and Eliminate the Heterogenous Population Associated with AML

Zachary Davis, Frank Cichocki, Martin Felices, Hongbo Wang, Peter Hinderlie, Mark Juckett, Joseph Maakaron, Gregory I. Berk, Bryan Hancock, John Goulding, Ryan Bjordahl, Bahram Valamehr, Jeffrey S. Miller, MD

Blood (2022) 140 (Supplement 1): 10288–10289.

https://doi.org/10.1182/blood-2022-168981

Published: 2022

Journal Articles

Efficacy of CD19 Directed Therapies in Large B-Cell Lymphoma (LBCL) Relapsing after Chimeric Antigen Receptor (CAR) T-Cell Therapy

Blood (2022) 140 (Supplement 1): 10396–10398.

https://doi.org/10.1182/blood-2022-169689

Published: 2022

Journal Articles

Magrolimab in Combination with Rituximab + Chemotherapy in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Joseph Maakaron, Adam S. Asch, Leslie L. Popplewell, Graham P. Collins, Ian W. Flinn, Nilanjan Ghosh, Colin Keane, Matthew Ku, Amitkumar Mehta, Mark Roschewski, Carol O'Hear, Xuehan Ren, Bertha Villa, Indu Lal, Sonali M. Smith, Ranjana H. Advani

Blood (2022) 140 (Supplement 1): 3728–3730.

https://doi.org/10.1182/blood-2022-167772

Published: 2022

Journal Articles

Icans Prophylaxis with Simvastatin and Intrathecal Dexamethasone in Adults Receiving Axicabtagene Ciloleucel (Axi‐Cel) Treatment

Joseph Maakaron, Emily Stene, Megan Bruns, Todd E. DeFor, Najla H El Jurdi, Veronika Bachanova, Daniel J. Weisdorf, Jeffrey S. Miller, Murali Janakiram, Mark Juckett

Blood (2021) 138 (Supplement 1): 1744.

https://doi.org/10.1182/blood-2021-149607

Published: 2021

Journal Articles

Phase I Dose-Escalation Study of Venetoclax Plus BEAM Followed By Autologous Stem Cell Transplant (ASCT) for Chemoresistant or High-Risk Relapsed/Refractory Non-Hodgkin Lymphoma (NHL)

Joseph Maakaron, Qiuhong Zhao, Jayalakshmi Panicker Balakrishna, Marcin Puto, Wesley Ferguson, Sam Penza, Jonathan E Brammer, Kami J. Maddocks, Yvonne A. Efebera, Ayman Saad, Samantha Jaglowski, Basem M. William

Blood (2021) 138 (Supplement 1): 656.

https://doi.org/10.1182/blood-2021-149580

Published: 2021

Journal Articles

Ruxolitinib Plus Nivolumab in Patients with R/R Hodgkin Lymphoma after Failure of Check-Point Inhibitors: Preliminary Report on Safety and Efficacy

Veronika Bachanova, Livia Hegerova, Qing Cao, Murali Janakiram, Joseph Maakaron, Sabarish Ayyappan, Daniel J. Weisdorf, Jaroslav Zak, Umar Farooq, Vaishalee P. Kenkre

Blood (2021) 138 (Supplement 1): 230.

https://doi.org/10.1182/blood-2021-149675

Published: 2021

Journal Articles

Predictive Factors and Outcomes for Ibrutinib Therapy in Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter Cohort Study

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-135870

Published: 2020

Journal Articles

Prognostic Impact of a Modified European LeukemiaNet (ELN) Genetic Risk Stratification in Predicting Outcomes for Adults with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HCT). a Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis for the CIBMTR Acute Leukemia Writing Committee

Blood (2020) 136 (Supplement 1): 27–29.

https://doi.org/10.1182/blood-2020-137589

Published: 2020

Journal Articles

Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer (NK) Cells in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma

Veronika Bachanova, MD PhD, Joseph Maakaron, MD, David H. McKenna, MD, Qing Cao, MS, Todd E. DeFor, MS, Fiona He, MD, Murali Janakiram, MD, Rose Wangen, Zuzan Cayci, MD, Bartosz Grzywacz, MD, Ronit Simantov, MD, Tracey Lodie, PhD, Jeffrey S. Miller, MD

Blood (2020) 136 (Supplement 1): 6.

https://doi.org/10.1182/blood-2020-142419

Published: 2020

Journal Articles

Impact of Age on the Outcomes of HCT for AML in CR1: Promising Therapy for Older Adults

Joseph Maakaron, MD, Karen Chen, MS, Mei-Jie Zhang, PhD, Christopher S. Hourigan, MDDPhil, Mark Litzow, MD, Wael Saber, MD MS, Partow Kebriaei, MD, Daniel J. Weisdorf, MD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-141096

Published: 2020

Journal Articles

Phase I Dose-Escalation Study of Venetoclax Plus BEAM Followed By Autologous Stem Cell Transplant (ASCT) for Chemoresistant or High-Risk Relapsed/Refractory Non-Hodgkin Lymphoma (NHL)

Joseph Maakaron, MD, Qiuhong Zhao, MS, Marcin Puto, PharmD, Quinn Verfurth, Sam Penza, MD, Jonathan E Brammer, MD, Yvonne A. Efebera, MD MPH, Ashley E. Rosko, MD, Ayman Saad, MD, Samantha Jaglowski, MDMPH, Basem M. William, MRCP,MD

Blood (2019) 134 (Supplement_1): 2024.

https://doi.org/10.1182/blood-2019-126994

Published: 2019

Journal Articles

Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial

Basem M. William, MRCP,MD, Ying Huang, MS, MA, Amy Johnson, MD, Jonathan E Brammer, MD, John C. Reneau, MD PhD, Joseph Maakaron, MD, Ruth Larbi, Cara Grantier, CNP, MPH, MS, Corinne Hoffman, MS, CNP, Sabarish Ayyappan, MBBS, Robert A Baiocchi, MD PhD, Narendranath Epperla, MDMS, Beth A. Christian, MD, Lapo Alinari, MD PhD, Kami J. Maddocks, MD, Catherine Chung, MD

Blood (2019) 134 (Supplement_1): 2853.

https://doi.org/10.1182/blood-2019-123801

Published: 2019

Journal Articles

Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity

Blood (2018) 132 (Supplement 1): 92.

https://doi.org/10.1182/blood-2018-99-117199

Published: 2018

Journal Articles

Procalcitonin As a Potential Biomarker for Differentiating Bacterial Infectious Fevers from Cytokine Release Syndrome

Joseph Maakaron, MD, Sam Penza, MD, Zeinab El Boghdadly, MBBCh, Caron A. Jacobson, MD, Bradley Hunter, MD MPH, Matthew J. Frigault, MD, Jeremy S. Abramson, MD MMSc, Justin Kline, MD, Jonathon B. Cohen, MD MS, Ajay K. Gopal, MD, Utkarsh H. Acharya, DO, Samantha Jaglowski, MD MPH, Philippe Armand, MD PhD

Blood (2018) 132 (Supplement 1): 4216.

https://doi.org/10.1182/blood-2018-99-120065

Published: 2018

Journal Articles

Decitabine Super-Responders: Challenging the Dogma of Long-Term Remission for Acute Myeloid Leukemia

Joseph Maakaron, MD, Gabriel N. Mannis, MD, Alison R. Walker, MD, Alice S. Mims, MD

Blood (2018) 132 (Supplement 1): 5190.

https://doi.org/10.1182/blood-2018-99-119916

Published: 2018

NARROW

Investigating the Novel Combination of the Innate Cell Engager (ICE®) Acimtamig with Off-the-Shelf Allogeneic Natural Killer Cells AlloNK® in Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Initial Results of the Phase 2 Luminice-203 Study

A Novel Dual-Antigen Targeting Approach Enables Off-the-Shelf CAR NK Cells to Effectively Recognize and Eliminate the Heterogenous Population Associated with AML

Efficacy of CD19 Directed Therapies in Large B-Cell Lymphoma (LBCL) Relapsing after Chimeric Antigen Receptor (CAR) T-Cell Therapy

Magrolimab in Combination with Rituximab + Chemotherapy in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Icans Prophylaxis with Simvastatin and Intrathecal Dexamethasone in Adults Receiving Axicabtagene Ciloleucel (Axi‐Cel) Treatment

Phase I Dose-Escalation Study of Venetoclax Plus BEAM Followed By Autologous Stem Cell Transplant (ASCT) for Chemoresistant or High-Risk Relapsed/Refractory Non-Hodgkin Lymphoma (NHL)

Ruxolitinib Plus Nivolumab in Patients with R/R Hodgkin Lymphoma after Failure of Check-Point Inhibitors: Preliminary Report on Safety and Efficacy

Predictive Factors and Outcomes for Ibrutinib Therapy in Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter Cohort Study

Results of a Phase 1 Trial of Gda-201, Nicotinamide-Expanded Allogeneic Natural Killer (NK) Cells in Patients with Refractory Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma

Impact of Age on the Outcomes of HCT for AML in CR1: Promising Therapy for Older Adults

Phase I Dose-Escalation Study of Venetoclax Plus BEAM Followed By Autologous Stem Cell Transplant (ASCT) for Chemoresistant or High-Risk Relapsed/Refractory Non-Hodgkin Lymphoma (NHL)

Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial

Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity

Procalcitonin As a Potential Biomarker for Differentiating Bacterial Infectious Fevers from Cytokine Release Syndrome

Decitabine Super-Responders: Challenging the Dogma of Long-Term Remission for Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only